SCHEDULE 13G/A: ARK Investment Management Discloses 8.80% Stake in CRISPR Therapeutics AG

ARK Investment Management LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.80% in CRISPR Therapeutics AG as of September 30, 2024.

Summary

• ARK Investment Management LLC, a Delaware-based investment adviser, reported beneficial ownership of 7,498,625 shares of Common Stock in CRISPR Therapeutics AG.
• This ownership represents 8.80% of the total class of securities outstanding.
• Of the total shares, ARK Investment Management LLC holds sole voting power over 7,067,364 shares and shared voting power over 173,350 shares.
• The firm also holds sole dispositive power over 7,498,625 shares and no shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics AG.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates continued significant investment by a prominent institutional firm, suggesting confidence in the issuer. However, it's a routine disclosure and not indicative of new strategic developments from the issuer.

Positives

• The disclosure of a significant stake by a prominent investment firm like ARK Investment Management LLC can be interpreted as a vote of confidence in CRISPR Therapeutics AG's long-term prospects and its gene-editing technology.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from ARK Investment Management LLC's Chief Compliance Officer)

Industry Context

ARK Investment Management is known for its focus on disruptive innovation, including investments in the biotechnology and genomics sectors. CRISPR Therapeutics AG is a leading company in the gene-editing space, making it a natural fit for ARK's investment strategy. This filing indicates continued significant institutional interest in the advanced therapeutic industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence investor sentiment and perception of the company's stability and attractiveness to large funds.

Key Dates

Keywords

CRISPR Therapeutics AG, ARK Investment Management LLC, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Gene Editing, Institutional Investor